Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.
|Numero di pagine||7|
|Rivista||CURRENT PHARMACEUTICAL DESIGN|
|Stato di pubblicazione||Published - 2008|
All Science Journal Classification (ASJC) codes
- Drug Discovery